Holen Sie sich die Stockscreener-App
2.355
1.07%
0.025
Schlusskurs vom Vortag:
$2.33
Offen:
$2.34
24-Stunden-Volumen:
29,793
Relative Volume:
0.87
Marktkapitalisierung:
$7.86M
Einnahmen:
$556.00K
Nettoeinkommen (Verlust:
$-5.28M
KGV:
-1.1005
EPS:
-2.14
Netto-Cashflow:
$-6.23M
1W Leistung:
+2.78%
1M Leistung:
-25.94%
6M Leistung:
-24.52%
1J Leistung:
-18.51%
1-Tages-Spanne:
$2.30
$2.44
1-Wochen-Bereich:
$2.10
$2.56
52-Wochen-Spanne:
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Firmenname
Cyclerion Therapeutics Inc
Sektor
Branche
Telefon
617-621-7722
Adresse
301 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie CYCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
2.355 | 8.30M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-20 | Eingeleitet | Truist | Buy |
| 2021-09-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-03 | Eingeleitet | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Aktie (CYCN) Neueste Nachrichten
Top chart patterns to watch in Cyclerion Therapeutics Inc.2025 Price Momentum & AI Forecasted Entry and Exit Points - Newser
How to forecast Cyclerion Therapeutics Inc. trends using time seriesMarket Risk Report & Real-Time Volume Analysis - Newser
Heatmap analysis for Cyclerion Therapeutics Inc. and competitorsJuly 2025 Weekly Recap & Capital Efficiency Focused Strategies - Newser
Will Cyclerion Therapeutics Inc. outperform the marketJuly 2025 Opening Moves & Free Weekly Watchlist of Top Performers - Newser
Chart based exit strategy for Cyclerion Therapeutics Inc.Product Launch & Comprehensive Market Scan Reports - Newser
What’s the recovery path for long term holders of Cyclerion Therapeutics Inc.2025 Retail Activity & Accurate Buy Signal Notifications - Newser
How to build a dashboard for Cyclerion Therapeutics Inc. stockPortfolio Growth Summary & Low Drawdown Trading Techniques - Newser
Using data tools to time your Cyclerion Therapeutics Inc. exitJuly 2025 Analyst Calls & Intraday High Probability Setup Alerts - Newser
What’s the recovery path for long term holders of MIRA Pharmaceuticals Inc.Trend Reversal & Accurate Entry/Exit Alerts - Newser
Using portfolio simulators with Cyclerion Therapeutics Inc. includedExit Point & Momentum Based Trading Ideas - Newser
Is Cyclerion Therapeutics Inc. showing signs of accumulation2025 Trading Recap & Verified Swing Trading Watchlists - Newser
Quantitative breakdown of Cyclerion Therapeutics Inc. recent moveQuarterly Profit Review & Low Risk High Win Rate Stock Picks - Newser
Will Cyclerion Therapeutics Inc. rebound enough to break even2025 Dividend Review & Risk Managed Investment Strategies - Newser
Institutional scanner results for Cyclerion Therapeutics Inc.Free Short Term Trading Opportunity Watch - Newser
Does Cyclerion Therapeutics Inc. show high probability of reboundPrice Spike Prediction for Active Traders - Newser
Earnings visualization tools for Galectin Therapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser
Can machine learning forecast Cyclerion Therapeutics Inc. recoveryYearly Trend Summary and Opportunity Breakdown - Newser
How Cyclerion Therapeutics Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
Cyclerion Therapeutics Inc. stock chart pattern explainedChart Driven Opportunity Scanner with Alerts - Newser
Is TWO.PRA trending in predictive chart modelsSecure Entry Point Finder with Analysis - Newser
Cyclerion Therapeutics, Inc. SEC 10-Q Report - TradingView
Finanzdaten der Cyclerion Therapeutics Inc-Aktie (CYCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):